Form 4: Director Athena Countouriotis Receives BMRN Stock Grant

BioMarin Pharmaceutical Inc. director Athena Countouriotis was granted 7,490 restricted stock units as part of equity compensation.

Summary

• Director Athena Countouriotis acquired 7,490 shares of BioMarin Pharmaceutical Inc. (BMRN) common stock.
• The transaction occurred on June 2, 2026, in the form of a restricted stock unit (RSU) grant.
• The acquisition price was $0, as these represent equity-based compensation.
• Following this transaction, the director's total beneficial ownership increased to 21,040 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation.

Positives

• Alignment of director interests with shareholders through increased equity ownership.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• None identified; this is a standard equity compensation disclosure.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation practices for mid-to-large cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• None identified.

Key Dates

Keywords

BioMarin, BMRN, Form 4, Insider Trading, Equity Compensation, Director Ownership